We studied covariability of selected amino acid positions in globally dominant HIV-1 subtype C viruses. The analyzed sequences spanned the V3 loop, Gag p17, Gag p24, and five CTL epitope-rich regions in Gag, Nef, and Tat 
INTRODUCTION S TATISTICAL COVARIABILITY OF AMINO ACID MUTATIONS
AMONG SITES IN HIV-1 amino acid sequences may indicate interesting biological interactions between the sites. The interactions may reflect functional constraints of protein structure, motivating analyses that search for covarying sites. Korber et al. 1 analyzed for covariability 308 subtype B V3 loop amino acid sequences and identified seven highly significantly covarying pairs of sites. Bickel et al. 2 followed up this study by analyzing the same set of V3 loop sequences plus a second set of 248 subtype B V3 loop sequences and 192 non-subtype B sequences. This analysis identified 8-20 highly significantly covarying pairs of sites, including 5 of those found earlier. 1 Many of the covarying sites identified by these studies have known important biological functions, illustrating the potential value of covariability analyses for predicting critical structural features of HIV-1 proteins as targets for vaccines and therapies. In addition, Brown et al., 3 Hoffman et al., 4 and Wu et al. 5 studied covariability of HIV-1 protease amino acids and related the results to HIV-1 function or structure.
Due to the dearth of subtype C sequences in databases at the time of their analyses, the earlier work 1, 2 could not study the covariability of subtype C sequences. Ample data on HIV-1C sequences have now accrued. [6] [7] [8] [9] [10] Given the recent expansion of the subtype C epidemic to its present global predominance, [11] [12] [13] [14] and the increasing emphasis of HIV-1 vaccine research toward subtype C viruses, it is important to analyze for covariability subtype C sequences. Furthermore, up to the time of the analysis of Bickel et al., 2 much of HIV vaccine research had focused on envelopebased vaccines for which studying the V3 loop was of paramount interest. Since then, the field has increasingly invested in vaccine design of nonenvelope genes such as gag, nef, and tat. 15, 16 In this article, we analyze for covariability HIV-1 subtype C sequences predominantly from southern Africa, in the V3 loop as well as in Gag p17, Gag p24, and regions in Gag, Nef, and Tat that have been found to be rich with cytotoxic T lymphocyte (CTL) epitopes in HIV-1C. 17, 18 The latter regions are important to study be-cause several HIV-1 vaccine candidates under development are based on eliciting CTL responses to these regions. 15, 16, 19 In the selected regions, we also compare the covariability of subtype C sequences to that in subtype B sequences. This comparison provides a way to identify subtype-specific covariability.
Five immunodominant regions within HIV-1C were identified in our previous study; 18 two in Gag p24, spanning positions 171-190 and 291-320; two in Nef, in positions 67-96 and 122-141; and one in Tat, in positions [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . Throughout this article the amino acid positions are relative to the HXB2 numbering system. 20 In addition to the CTL epitopes within HIV-1B Gag and Nef that were described previously, 17 Elispot-based CTL responses to HIV-1B Gag p24 (positions 171-190) and HIV-1B Nef (positions 71-90 and 131-150) have recently been reported. 21, 22 In addition to reporting on covariability results for HIV-1 subtypes and proteins previously not evaluated, this article applies new quantitative methods for studying covariability that build upon the existing methods. 1, 2 The new techniques include two statistics for quantitating the extent of covariation between pairs of sites with confidence intervals, including a normalized mutual information statistic that helps correct the problem of relatively low power to detect covariability among conserved positions. A normalized version of the mutual information statistic is also used for evaluating covariation of triples of sites.
This study identified a large number of covarying site pairs and triples in HIV-1C and HIV-1B, and located covariable-rich regions, some common to the subtypes and some subtype specific. To attempt to determine the biological significance of the covariability findings, dN Ϫ dS rate differences and sequence diversity were examined in the regions evaluated for covariability. The analyses support biologically important covariation of certain amino acids sites, although data are limited for confirming the significance of the results. Such statistical findings are important because they generate hypotheses about biological function that can be tested in future experiments.
MATERIALS AND METHODS
The purpose of the methods is to detect pairs of sites i, j (or triples i, j, k) in HIV-1 amino acid sequences that covary in a statistically significant way. We briefly summarize the methods applied by Bickel et al., 2 and then describe the new methods. For a pair of sites i and j, Bickel et al. 2 considered three statistical criteria for measuring the evidence for covariation. The first statistic is the mutual information M ij , also used by Korber et al., 1 which is the likelihood ratio statistic for testing independence of two sites versus arbitrary covariation. This statistic is equivalent to the maximum likelihood estimator of linkage disequilibrium developed by Hill. 23 For large samples M ij is approximately equivalent to Pearson's 2 statistic for testing independence. The second statistic, G ij , has a heuristic interpretation described in Goodman and Kruskal 24 as the average increase in the chance of guessing correctly the residue at i based on knowing both the residues at sites i and j compared to knowing only the residues at i. To describe the third statistic P ij , consider Weir and Cockerham's 25 statistic P ij (a,b), which is the likelihood ratio statistic for testing independence of sites i and j versus the alternative that the pair of residues (a, b) is favored relative to what is expected by chance. Bickel et al. 2 defined P ij as the maximum of the P ij (a, b) statistics over the 400 pairs of residues a and b. Like M ij , P ij is similar to the 2 statistic, except that P ij is designed to detect covariation driven by a single pair of residues.
The statistic M ij has relatively low power to detect covariability of conserved positions, which may be disadvantageous given the functional significance often associated with conserved regions. To remedy this problem, we also used a normalized version of M ij , M* ij , that weights positions equally regardless of diversity, and ranges between 0 and 1. All four statistics M ij , M* ij , G ij , and P ij are always nonnegative, with value zero reflecting no covariation and large values indicating covariation. To test whether HIV-1C and HIV-1B sequences had different degrees of covariability at two positions i and j, we used the difference in M* ij values as a test statistic, and applied the nonparametric bootstrap to obtain an unadjusted p-value. The statistics are defined mathematically in the Appendix.
The covariability statistics may potentially be improved by upweighting covarying mutations present in phylogenetically distantly related sequences, as they are more informative about covariation than mutations in phylogenetically similar sequences. 1 This was done for the M ij and M* ij statistics by incorporating a weight function into the statistics as detailed in the Appendix. The results were similar to those obtained without the weighting.
For sequences of length q, there are q ϫ (q Ϫ 1)/2 pairs of sites that could potentially covary. Korber et al. 1 and Bickel et al. 2 studied globally gap-stripped V3 loop sequences of length q ϭ 31, so that 31 ϫ 30/2 ϭ 465 pairs of sites were studied. Bickel et al. 2 computed the three statistics for each pair, and used a permutation procedure to obtain p-values for each pair of sites (i, j). The resulting p-values are not adjusted for the many tests that were conducted, and must be adjusted to avoid many false-positive discoveries. We used the same permutation procedure as Bickel et al. 2 for computing unadjusted p-values, but applied a more powerful procedure of p-value adjustment that detects covarying positions with greater probability.
Adjusting for the multiplicity of tests
Bickel et al. 2 used a Bonferroni correction to judge statistical significance of the hundreds of covariation tests, which amounts to using p ϭ 0.05/465 ϭ 0.00011 as a cut-off value for comparison with each unadjusted p-value pval ij to judge whether the site pair i, j "significantly covaries." The Bonferroni method provides stringent control of the false-positive rate, guaranteeing at most a 5% chance that there are any false rejections. However, if the test statistics are positively correlated across pairs of sites, which is likely the case, then the Bonferroni procedure can be extremely conservative. The cost of the conservative approach is a higher rate of false negatives (i.e., truly covarying pairs that are not identified), which is exacerbated most when q is large, because the Bonferroni correction becomes increasingly (and extremely) conservative with the number of tests. To improve power we used the now-popular false discovery rate (FDR) method for multiple testing adjustment. 26 Given K unadjusted p-values, the FDR procedure works as follows: order the K p-values from smallest to largest, and let k* be the largest integer k such that the kth largest p-value is less than or equal to (k ϫ ␣)/K. The tests corresponding to the k* smallest p-values are then declared significant at level ␣. With this simple procedure, the expected number of significant test results that are false rejections is no greater than ␣. The FDR procedure has greater statistical power than the Bonferroni procedure, especially when there are a large number of tests (our case), since the FDR method does not become conservative as the number of tests increases. We applied both the Bonferroni and FDR methods.
Estimating the extent of covariability
We used a new measure, C ij , of the degree of covariation for a pair (i, j) of sites, which is related to the test statistic P ij . Let a and b be the consensus amino acids at positions i and j, respectively. The measure C ij is the geometric mean of the proportion of sequences in which a non-a amino acid at site i is accompanied by a non-b amino acid at site j, and the proportion of sequences in which a non-b amino acid at site j is accompanied by a non-a amino acid at site i (see the Appendix for a formula for C ij ). C ij measures general covariation of residues away from the consensus pair, and ranges between 0 (no covariation) and 1 (perfect covariation). A confidence interval (CI) for the degree of covariation was constructed using the nonparametric bootstrap. C ij will be most useful when the modal amino acids have high prevalence, which is usually the case: 83.4%, 94.8%, and 83.8% of the positions in HIV-1C Gag p17, Gag p24, and the V3 loop that we studied had consensus amino acids in 80% or more of the sequences. Because M* ij and G ij range between 0 and 1, they are also useful as estimates of the extent of covariation.
A test statistic for higher-order covariability
To study covariability of triples of sites, we used the mutual information statistic M ijk generalized to measure covariability of three sites (defined in the Appendix). This statistic is equivalent to the estimator of three-way disequilibrium developed by Weir. 28 We also used a normalized version of M ijk , M* ijk that had been proposed 29 (defined in the Appendix). Studying covariability of site pairs and triples with the mutual information statistic has the advantage of providing a unified analysis of covariability, and its application is simpler and more straightforward than the secondorder log-linear categorical models used by Bickel et al. 2 
dN Ϫ dS estimates
For all positions in the evaluated regions, nonsynonomous (dN) minus synonomous (dS) rate differences dN Ϫ dS, scaled to represent the expected number of nucleotide substitutions per codon site, were estimated using the single most likely ancestral reconstruction maximum likelihood method. 30 A dN Ϫ dS rate difference of 0 means neutral mutations, a difference Ͻ0 indicates purifying selection, and a difference Ͼ0 represents diversifying positive selection. 31 Spearman rank correlation coefficients and tests were used to assess associations between covariability statistics and dN Ϫ dS values at pairs of positions.
Amino acid diversity
To analyze amino acid diversity of regions, pairwise amino acid distances were computed using the PROTDIST program with the PAM model 32 as described previously. 9 For each region, a two-sided Z-test was used to compare the mean diversity between subtypes. The test statistic equals the difference in mean pairwise diversity divided by the standard error of the difference, which was computed with appropriate account for the correlations in pairwise distances. 27 
Selection of amino acid sites for analysis
Many of the positions in the regions we studied were highly conserved across the studied sequences, and hence contained little information about covariability. Positions at which fewer than two sequences within a subtype had a nonconsensus amino acid were not evaluated.
First, we analyzed 264 HIV-1C V3 loop sequences in the Los Alamos database sampled from the southern African nations Botswana (n ϭ 51), Malawi (n ϭ 80), Mozambique (n ϭ 7), South Africa (n ϭ 91), Zambia (n ϭ 4), and Zimbabwe (n ϭ 31). 33 HIV-1C V3 loop sequences from other geographic regions were excluded to help avoid bias and to aid interpretability. The aligned sequences spanned 37 positions, 27 of which had enough diversity to be investigated for covariability. We evaluated all 27 ϫ 26/2 ϭ 351 viable pairs for covariability. Second, we analyzed the p17 and p24 regions of 73 nonrecombinant HIV-1C Gag sequences described in Novitsky et al., 9 sampled from Botswana (n ϭ 51), South Africa (n ϭ 5), Tanzania (n ϭ 2), Zambia (n ϭ 2), Brazil (n ϭ 2), Ethiopia (n ϭ 1), India (n ϭ 9), and Israel (n ϭ 1). The analyzed p17 and p24 regions comprised 145 and 231 positions in alignment, respectively. The sequence lengths imply that there are 10,440 and 26,565 pairs of positions that potentially may covary. Analysis of this many pairs is highly demanding computationally; to make it viable, we reduced the number of sites to those at which the consensus amino acid had frequency less than 90%. This restriction reduced the number of positions to 38 and 22 for p17 and p24, respectively. Third, using the same set of 73 HIV-1C sequences, we analyzed separately the five immunodominant regions of Gag, Nef, and Tat described in the Introduction: Gag 171-190, Gag 291-320, Nef 67-96, Nef 122-141, and Tat 36-50. For the Tat region, one sequence was excluded because an approximately 500 base pair deletion eliminated its first exon. For these immunodominant regions, 1 of 20, 6 of 30, 10 of 30, 6 of 20, and 4 of 15 positions, respectively, had sufficient variability to be evaluated for covariability, so that 0, 15, 45, 15, and 6 pairs of positions were evaluated. After identifying the sites that significantly covaried within individual epitope-rich regions, we searched for cross-epitope region covariability by analyzing these positions together.
For each pair of sites (i, j) identified to significantly covary by the FDR method, we used the statistical criteria M ijk and M* ijk to search for covariability of the triples (i, j, k), for k ranging over all sites other than i and j with at least one significant connection. These analyses were carried out separately within the eight regions studied.
The analyses described above were repeated in 264 HIV-1B V3 loop sequences and 73 HIV-1B sequences selected randomly from the Los Alamos sequence database 33 For Gag p17 and Gag p24, the HIV-1B positions corresponding to those evaluated in HIV-1C were analyzed. However, whereas all of the studied positions in Gag p17 and Gag p24 for HIV-1C had consensus amino acid frequency less than 90%, many of the corresponding positions for HIV-1B did not. To allow subtype comparisons of the extent of covariability, supplementary analyses were done at all HIV-1B Gag p17 and Gag p24 positions with more than 10% variability, which amounted to 35 and 15 positions, respectively.
The translated amino acid sequence sets were aligned using ClustalX v.1.81 34 and manually edited using BioEdit. 35 For the covariability analyses gaps were treated as a twenty-first residue. p-values in covariability analyses were calculated using 10,000 randomly permuted datasets. Bootstrap samples (5000) were used for computing CIs about the covariation parameters estimated by C ij or M* ij .
RESULTS
In HIV-1C viral sequences, we found several significantly covarying pairs in the V3 loop, in Gag p17, and in epitoperich region Nef 67-96, a small number of significantly covarying pairs in Gag p24, Gag 291-320, and Tat 36-50, and no covarying pairs in Gag 171-190 or Nef 122-141. In HIV-1B viruses, a very large number of site pairs significantly covaried in the V3 loop, a large number covaried in Gag p17, Gag p24, and Nef 122-141, a small number covaried in Nef 67-96 and Tat 36-50, and none covaried in Gag 171-190 and Gag 291-320. As judged by significance of at least one of the four statistical criteria, the FDR procedure was much more powerful in detecting covariation than the Bonferroni procedure, yielding a total of 321 discoveries of significantly covarying pairs, compared to 131 by the Bonferroni procedure (Table 1 ). Of the discoveries by FDR and by Bonferroni, respectively, 52 (16.2%) and 23 (17.6%) covarying pairs were in HIV-1C; the decreased covariability in HIV-1C was mostly due to the V3 loop and Gag p17. In contrast, only Nef 67-96 and Gag 291-320 showed more covariability in HIV-1C. We describe important details of the results by region.
V3 loop
Within HIV-1C, 17 pairs of V3 loop amino acids significantly covaried (Table 1 Table 2 ). T297 indicates that the consensus residue is T at position 297.
show only connections with relatively robust evidence of covariability (i.e., connections significant by two or more statistics), while Table 1 To place our results in the context of the earlier work, in Fig. 2 we marked the highly significant site pairs found by Korber et al. 1 ("K"), Bickel et al. 2 ("B"), and both studies ("KB"). Of the 7 HIV-1B site pairs identified as strongly covarying by Korber et al. 1 1B our analysis also found covariability of 9 of the 20 strongly covarying site pairs identified by Bickel et al. 2 (see the 20 bolded site pairs in their Fig. 1 ). In total we corroborated covariation of 13 site pairs in HIV-1B previously identified, and we found 27 covarying site-triples that involved one of these site pairs (further results on covarying site triples are given below). Both previous papers concluded that positions 306, 308, and 318-322 appeared to be most important for covariability, and interestingly these positions stood out in our analysis as participating in extensive covariability; no- 
Gag p17
In HIV-1C, 18 pairs significantly covaried in Gag p17 (Tables 1 and 2; Fig. 3, upper-left matrix) . For the corresponding Gag p17 positions in HIV-1B, 7 pairs significantly covaried. Two pairs of sites had significantly greater covariation in HIV-1C than HIV-1B (15-90, 28-30) , and one site pair had significantly greater covariation in HIV-1B than HIV-1C (93-125).
The analysis of HIV-1B Gag p17 positions with more than 10% variability showed a large number of covarying pairs, with 59 total connections (Tables 1 and 2 
Gag p24
In HIV-1C Gag p24, three site pairs significantly covaried. There were twice as many (6) significant connections in the corresponding positions of HIV-1B (Fig. 3, upper-right matrix) . Although none of the covarying pairs was common among the subtypes, notably position 252 was important for both subtypes. Four site pairs covaried significantly more in HIV-1C (159-312, 159-252, 219-228, 228-252) and two site pairs covaried significantly more in HIV-1B (91-116, 98-120).
The analysis of HIV-1B Gag p24 positions with more than 10% variability showed more extensive covariability than for HIV-1C Gag p24 (Fig. 3, lower-right matrix) . Sixteen pairs significantly covaried, with pairs 159-280 and 211-280 showing strong covariation.
HIV-1C CTL epitope-rich regions
In HIV-1C Gag 171-190, all positions but one were too conserved to assess covariability; therefore no pairs were evaluated. Only one site pair was evaluable in HIV-1B Gag 171-190, without significant covariation. Three site pairs significantly co- In the cross-epitope region analysis for HIV-1C, 13 significant connections were found. Of these, 12 pairs were within one of the epitope-rich regions (i.e., they were discovered in the region-specific analysis). The one (weakly) significant covariable pair with sites in different epitope-rich regions involved positions 88 in Nef 67-96 and 315 in Gag 291-320, with C ij ϭ 0.387 (95% CI 0.000-0.564). The consensus pair S, N covaried to G, A; G, G; and D, G in one sequence each. 
Analysis for covariability of triples of sites

Normalized dN Ϫ dS differences associated with degree of covariability
For each region, correlations between the average normalized dN Ϫ dS value for each pair (i, j) of positions and the C ij covariability statistics were assessed. There were moderate or weak correlations in both subtypes for the V3 loop, Gag p17, and Gag p24. For the HIV-1C V3 loop, the Spearman rank correlation r was 0.41 (p Ͻ 0.0001) between average normalized dN Ϫ dS and C ij , and for the HIV-1B V3 loop r ϭ 0.30 (p Ͻ 0.0001). For HIV-1C Gag p17, r ϭ 0.25 (p Ͻ 0.0001), whereas for HIV-1B Gag p17, r ϭ 0.12 (p ϭ 0.0054). In addition, for HIV-1C Gag p24 r ϭ 0.14 (p ϭ 0.04) and for HIV-1B Gag p24 r ϭ 0.39 (p Ͻ 0.0001). For the immunodominant regions a significant correlation was found only for HIV-1C Gag 291-320, with r ϭ 0.52 (p ϭ 0.05). Based on the hypothesis testing procedure, 30 for none of the site pairs with greatest evidence of covariability (those listed in Table 2 ) was there significant evidence (p Ͻ 0.05) that both sites were under selection pressure (i.e., dN Ϫ dS Ͼ 0).
Association of amino acid site covariability and diversity
Of the 8 regions evaluated for covariability, 2 showed comparable levels of covariability in subtypes C and B (Gag 171-190, and Tat 36-50), 4 showed less covariability in HIV-1C (V3 loop, Gag p17, Gag p24, Nef 122-141), and 2 showed more covariability in HIV-1C (Nef 67-96 and Gag 291-320). To help interpret these results, Table 3 summarizes the pairwise amino acid diversity of the regions. Six of the regions had significantly different mean diversity, including 5 of the 6 regions with subtype differences in the degree of covariability. For the V3 loop and Nef 122-141, the subtype with more covariability also had higher diversity. This correspondence may be explained partly by the fact that the statistical criteria have greater statistical power for detecting covariability in regions with greater diversity. This observation may help explain the extensive amount of covariability identified in the HIV-1B V3 loop, with its large mean diversity of 22.2%, compared to 14.5% for the HIV-1C V3 loop. The subtype difference in covariability for Nef 122-141 is too large to be explained fully by differential diversity, however. In addition, Gag p17 had considerably less covariation for HIV-1C but more diversity. This finding may be explained by the fact that Gag p17 is highly immunodominant in HIV-1B, containing many known CTL epitopes 17 ; the greater covariability may reflect the functional importance of HIV-1B Gag p17. This finding may also support GILBERT ET AL. 1026 a 95% confidence intervals (CIs) were computed as the mean difference in diversity plus or minus 1.96 times the standard error of the difference computed as described in Novitsky et al. 9 b Unadjusted p-value, computed using the two-sample Z-test summarized in Materials and Methods and detailed in Novitsky et al. 9 An asterisk implies the result is statistically significant at level 0.05 after FDR adjustment for eight hypothesis tests.
Diversity (%) Difference in diversity (C Ϫ B)
the higher fitness of HIV-1C, which is indirectly supported by the relatively high prevalence of HIV-1C.
Despite the observed relative conservancy of subtype C's V3 loop, the data suggest that HIV-1C may have a broader range of viable viruses than HIV-1B: of the 264 V3 loop sequences studied, 196 (74%) were distinct for HIV-1C, but only 144 (54%) were distinct for HIV-1B.
DISCUSSION
This study evaluated for covariability eight regions in HIV-1C and HIV-1B, and identified hundreds of significantly covarying pairs and triples of amino acids. We summarize the results, connecting the covariability findings to biological knowledge where possible.
In HIV-1C, several covarying pairs were identified in the V3 loop, Gag p17, Gag p24, Gag 291-320, Nef 67-96, and Tat Table 2 lists the site pairs with robust evidence of covariability.
Notably, greater covariability was found in the V3 loop and Gag p17 for subtype B, perhaps suggesting greater functional constraints in these regions for HIV-1B. In addition, the finding of strong covariability of site pair 309-312 in Gag 291-320 but no covarying pairs in the corresponding region for HIV-1B may reflect the fact that this region contains T cell epitopes for subtype C but not for subtype B. 18, 36 Similarly, in Nef 122-141, there were no significant covariable pairs in HIV-1C, but a plethora of connections in HIV-1B. This finding may reflect that this region, known to be part of the four-stranded antiparallel ␤-sheet of Nef, 37 is T cell epitope rich for subtype B but not for subtype C. In HIV-1C many T cell epitopes remain to be mapped, and the analysis reported here illustrates that covariability analyses complement direct mapping analyses, in these cases supporting that Gag 291-320 and Nef 122-141 merit special attention for HIV-1C and HIV-1B, respectively. Covariability within a type II polyproline helix that represents the main binding site for the Src family kinases 37 among positions 71-79 in Nef was found for subtype C, which may suggest the existence of compensatory mutations or linkage. This hypothesis is supported by the direct epitope mapping analyses, which showed that Nef 71-79 contains a T cell epitope for subtype C. 9, 38 In addition, there was strong evidence that amino acid positions 39, 40 in the core region of Tat covaried in both subtypes.
A recent study of a rhesus macaque infected with SHIV-89.6P demonstrates the utility of covariability analysis of CTL epitope regions; Peyerl et al. 39 used covariability analysis to help establish that a CTL epitope was structurally constrained from mutating to escape from CTL recognition. Amino acid mutation T47I at position 2 in an immunodominant Gag Mamu-A*01-restricted epitope coincident with mutation I71V in a flanking position led to SHIV-89.6P escape from the dominant epitope-specific CTL response. As measured by Gag protein expression, viral infectivity, and replication kinetics, the fitness of the virus with T47I mutation was greatly reduced compared to the wild-type virus, but when the T47I and I71V mutations were both present, the fitness was restored to wild-type levels. Through the analysis of SIV and HIV-2 sequences from the Los Alamos sequence database, 33 Peyerl et al. 39 showed strong covariability of positions 47 and 71 (Fisher's exact test p Ͻ 0.0005), and this result can be confirmed using the methods used here, which are more appropriate than Fisher's exact test. This example illustrates that covariability analyses are useful for understanding how viruses escape from CTL recognition.
For the V3 loop, Gag p17, and Gag p24 in both subtypes, we found significant correlations between the C ij statistics quantifying evidence for covariability and the normalized dN Ϫ dS differences. However, for most of the strongly covarying amino acid sites (Table 2) , there was no significant evidence that dN Ϫ dS Ͼ 0, and therefore the extent to which the covarying amino acids might be under selection pressure is unclear. We also identified several triples of sites that covaried in the HIV-1C V3 loop and a great number in the HIV-1B V3 loop (242 connections), a large number of covarying site triples in Gag p17 for both subtypes (87 for HIV-1C and 84 for HIV-1B), and several covarying site triples in HIV-1B Gag p24 (9, all involving key position 280).
Our analysis of the HIV-1B V3 loop corroborated several of biological observations. 1,2 de Jong et al. 40 found that mutations at positions 306 and positions within 319-322 are necessary for the HIV-1 phenotype to completely convert from NSI to SI, and we found strong covariability of position 306 with all four sites 319-322. Chesebro et al. 41 found that mutations at site 308 and sites within 318-322 are needed for a phenotype switch from T cell to macrophage tropic, and we found strong covariability of site 308 with sites 318, 321, 322. Site pairs 306-322 42 and 308-322 43 were found to be important for viral tropism. In addition to the observations made by Korber et al. 1 and Bickel et al. 2 on functional significance, positions 317 and 330 strongly covaried in HIV-1B (but not HIV-1C), and in mutagenesis experiments these sites were found to be important for CCR5 binding, soluble CD4 binding, and monoclonal antibody binding. 44 Position 297 showed extensive covariability in HIV-1B, and this position is in a neutralization epitope of monoclonal antibody 2G12. 45 Furthermore, position 301 is a potential N-linked glycosylation site for both subtypes (with NNT motif at positions 301-303 for most sequences), and site 301 covaried with site 303 for HIV-1C and with sites 300, 308, 323, and 326 for HIV-1B. Positions 301 and 303 have been implicated in immune escape. 46 These results may help the design of experiments that investigate the glycan shield as a mechanism of immune evasion. 47 The HIV-1B V3 loop exhibited more diversity and covariability than the HIV-1C V3 loop, yet had a smaller range of unique viruses. This observation suggests that mutations in the HIV-1B V3 loop occur "as a package" (several amino acid replacements tend to appear together), and supports interpreting the wealth of covariability as reflecting greater functional constraints within the HIV-1B V3 loop compared to HIV-1C. The decreased functional constraints in the V3 loop of HIV-1C relative to HIV-1B may reflect that HIV-1C is highly fit and is in some sense ideal for the subtype C environment. This hypoth-esis of greater fitness of the C versus B V3 loop could be tested experimentally by generating a number of mutated plasmids and analyzing their viral fitness. If changes in the HIV-1C V3 loop result in weaker viruses, then the experiment could explain why HIV-1C accumulates less mutations within the V3 loop, and could partially explain why HIV-1C rarely switches to the X4 phenotype during the course of HIV-1 disease. 48, 49 There are several limitations to our analysis that could cause observed covariability to be a sampling artifact. As also discussed by Korber et al. 1 and Bickel et al., 2 biases could result from (1) founder-virus effects, whereby statistical covariation may be observed between two sites because a group of viruses descended from a single ancestor virus; (2) unknown epidemiological clustering of some of the analyzed viruses; (3) the fact that data are sparse, with consensus amino acids presenting with high frequency with typically only a small number of other amino acids appearing; and (4) the sequences were not sampled randomly from a target population of interest (such as recent seroconverters in a geographic region where an HIV vaccine efficacy trial is being planned).
Unfortunately, because limited data are available on longitudinal sequence samples, especially for HIV-1C, it is not possible at this time to ascertain the potential impact of limitation (1); this is a general challenge faced in covariability analyses. The dN Ϫ dS analyses are limited by the lack of longitudinal sampling of sequences, which will be required to definitively test the hypothesis that covariable pairs are under evolutionary selection pressure. Moreover, the pattern for covarying sites to have higher dN Ϫ dS differences may have occurred in part because the test statistics have relatively high power for detecting covariability of sites with large dN Ϫ dS differences.
Problem (2) was partially alleviated by sampling the HIV-1C viruses across several countries in southern Africa, and by sampling the HIV-1B viruses randomly from the Los Alamos database. Limitation (3) complicates the study of higher order covariability of sites, and can make p-values sensitive to a small number of sequences. Focusing attention away from p-values and toward the newly proposed covariability summary measures C ij and M* ij eases the difficulty. The lower 95% confidence limits may be superior to p-values as measures of the reliability of the covariability findings.
To minimize limitation (4), to the extent possible, the analyzed HIV-1C viruses were selected from individuals with common characteristics. The V3 loop sequence dataset was geographically restricted to viruses known to come from southern African countries, and most of the Gag, Nef, and Tat sequences also came from southern Africa. In addition, most of the HIV-1C viruses were likely transmitted heterosexually, and most of the 51 HIV-1C viruses sampled from Botswana came from asymptomatic blood donors. 9, 18 Other than these selection criteria, the analyses of the sequence data are susceptible to limitation (4). In particular, common selection factors were not available for determining the set of HIV-1B sequences for the analysis.
In the face of the potential biases, a case for biologically important covariability of two sites can be built using information on the functional covariation of the sites in vitro and on the biological function of the sites. Verification of cross-clade covariability also lends support to biological covariability, as bias from a founder-virus effect is less likely.
Due to the limited knowledge about the functional significance of positions in HIV-1C, it is not possible at this time to verify that the identified covarying positions in HIV-1C have biological importance. The analyses generate hypotheses about functionally important sites, which merit investigation in future studies of viral function. If the covariability could be linked directly to functional or structural significance, then knowledge of the covarying sites may be useful for selecting the amino acid sequence(s) of the antigen(s) used in an HIV-1 vaccine, and for selecting the peptides to use in the evaluation of immunogenicity of HIV-1 vaccines. Even in the absence of biological links, information on covariability helps delineate the distribution of HIV-1 quasispecies in a population, which guides the selection of antigen sequences to give maximal vaccine coverage. Typically, assessments of HIV-1 amino acid diversity and variability have ignored information on covariability. We propose that covariability data should be used to improve such assessments.
Given the difficulty in interpreting results of analyses of haphazardly sampled sequence sets, we think that analyses of sequence sets with carefully constructed sampling plans will be of greatest value. The sample size for such studies may be modest, and therefore it is important to use powerful statistical procedures for maximizing signal detection, such as the FDR procedure used here. Color figures and online software for graphical display and testing of covariability are available from the first author (pgilbert@scharp.org).
APPENDIX: STATISTICS FOR MEASURING COVARIABILITY
In the notation of Bickel et al., 2 
